Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment

Save

Report Abuse

Description

Locoregional, intracavitary radioimmunotherapy (iRIT) with a newly developed radioimmunoconjugate (Lu-177 labeled 6A10-Fab-fragments) will be used to prevent or postpone tumour recurrence in patients with GBM following standard therapy .

Following study objectives will be analyzed:

Determining the Maximum Tolerated Dose (MTD)
Determining safety by assessing all new neurological, hematological and other AEs CTC grade 2 or higher
Determining absorbed dose to the 2 cm shell of the resection cavity (based on a series of SPECT/CTs of the head 2h,24h,48h, 72h p.i. and on day 5-7)
Determining absorbed dose values for the kidneys, the liver, the active marrow (based on a series of SPECT/CTs of the abdomen 2h,24h,48h, 72h p.i. and on day 5-7)
Determining 24 weeks Progression-Free-Survival (PFS), defined from the day of inclusion

Targeted Conditions

Study Overview

Start Date
January 22, 2024
Completion Date
June 1, 2025
Enrollment
15
Date Posted
September 8, 2022
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
Klinik für Neurochirurgie des Universitätsklinikums Essen
Essen 45147, Germany

Klinik für Nuklearmedizin, Strahlenklinik des Universitätsklinikums Essen
Essen 45147, Germany

Klinik für Allgemeine Neurochirurgie des Universitätsklinikums Köln
Köln 50937, Germany

Klinik für Nuklearmedizin des Universitätsklinikums Köln
Köln 50937, Germany

Klinik für Nuklearmedizin der Universität Münster
Münster 48149, Germany

Universitätsklinikum Würzburg - Neurochirurgie
Würzburg 97080, Germany

Universitätsklinikum Würzburg - Nuklearmedizin
Würzburg 97080, Germany

Eligibility

Minimum Age (years)
18
Maximum Age (years)
80
Eligibility Criteria
Inclusion Criteria:

Written patient consent after comprehensive information
Age between 18 and 80 years
Primary supratentorial high grade glioma after standard therapy (fluorescence-guided surgery, radio-chemotherapy, concomitant + adjuvant chemotherapy), with no or stable small tumor residue (residual contrast enhancement of up to 5cm3) at earliest 6 weeks after completion of radiotherapy
Histological verification of glioblastoma and CA 12-expression of tumor cells confirmed
Karnofsky-score ≥ 60
Volume of resection cavity 2,5-25 cm3
Male and female patients with reproductive potential must use an approved contraceptive method
Pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained prior to treatment start
Adequate bone marrow reserve: white blood cell (WBC) count ≥3000/μl, granulocyte count >1500/μl, platelets ≥100000/μl, hemoglobin ≥ 10 g/dl
Adequate liver function: bilirubin < 1.5 times above upper limit of normal range (ULN), alanine transaminase (ALT/SGPT) and aspartate transaminase (AST/SGOT) < 3 times ULN. In the case of documented or suspected Gilbert's disease bilirubin < 3 times ULN.
Blood clotting: INR (=PT) and PTT within acceptable limits according to the investigator
Adequate renal function: creatinine < 3 times above ULN; eGFR > (or equal) 60 ml/min

Exclusion Criteria:

Patient unable to undergo imaging by CT, PET or contrast-enhanced MRI for whatever reason (i.e., pacemaker)
Resection cavity with intraventricular access
Significant leakage of radioactivity into CSF spaces or ventricles
Other actively treated invasive malignancy
Breastfeeding women
Past medical history of diseases with poor prognosis, e.g., severe coronary heart disease, heart failure (NYHA III/IV), severe and poorly controlled diabetes, immune deficiency, residual deficits after stroke, severe mental retardation, pre-existing neurological diseases except those related to glioblastoma or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
Any active infection (at the discretion of the investigator)
Previous participation in a registered clinical trial with therapeutic intervention less than 6 weeks prior to enrolment (date of informed consent)
Allergy against known constituents of study medication

Study Contact Info

Study Contact Name
Walter Stummer, Prof. Dr.; Nils Warneke, Dr. med.
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
In glioblastoma (GBM), tumour recurrence occurs adjacent to the initial tumor resection cavity in about 85% of cases (Albert et al., 1994; Bashir et al., 1988; Nestler et al., 2015). Therefore, local treatment concepts seem crucial for effective recurrence treatment strategies. We consider locoregional, intracavitary radioimmunotherapy (iRIT) to be a new therapeutic approach to delay or prevent the development of local tumour regrowth in GBM patients. By applying a radioimmunoconjugate (RIC) into the surgically created resection cavity (RC) the blood-brain barrier can effectively be by-passed, allowing the a deposit of high radiation doses locally while sparing sensitive organs like the bone marrow and the kidneys. LuCaFab (Lu-177 labeled 6A10- Fab-fragment) is a carbonic anhydrase XII-specific antibody Fab fragment developed by Helmholtz Munich, labeled with ITM's highly pure medical radioisotope, lutetium-177. (ITM IsotopeTechnologies Munich SE). Patients with GBM after standard therapy (surgery by radio-chemotherapy concomitant and adjuvant chemotherapy) Are eligible for the study. Patients will receive the calculated total doses of Lu-177-labeled 6A10-Fabs in three fractions with an interval of 4 weeks between injections, administered into the tumour cavity via an implanted reservoir. A patient specific dosing strategy will be applied and will depend on the individual RC volume. This investigator-initiated trial is sponsored by the University Hospital Münster, conducted in hospitals in Münster, Essen, Cologne, and the Grosshadern Hospital Munich, and supported by ITM and Helmholtz Munich.
NCTid (if applicable)
NCT05533242